The cholinesterase inhibitors (ChEIs) donepezil, rivastigmine and galantamine are standard treatment for mildto-moderate Alzheimer's disease (AD). Generally ChEIs are well tolerated [1] , with a high retention rate [2] . Common adverse events (nausea, vomiting, diarrhoea, insomnia, muscle cramps) are related to cholinergic stimulation. The British National Formulary also lists headache as a side effect. Pooled donepezil clinical trial data indicated 8%-13% of patients experienced headache as an adverse event (vs. 9% in placebo group), which was considered medication-related in about half the patients [3] . To further investigate this, an observational study to measure headache frequency in a Cognitive Function Clinic population prescribed ChEIs was undertaken.
Over a 5.5-year period (January 2001-June 2006 inclusive), 143 patients were commenced on ChEIs (Table 1 ). In addition to planned follow-up, patients and caregivers were provided with a telephone contact number in case of adverse drug effects.
Two men (aged 70 and 56 years) with mild-to-moderate AD (Mini-Mental State Examination [MMSE] scores 25/30 and 23/30, respectively) complained of new daily headaches with features of tension-type headache within days of commencing donepezil at a low dose (5 mg/day). Headaches were continuous, global in distribution, aching in nature and unrelated to posture. One man noted headache improvement on lying still; he withdrew from treatment, with cessation of headaches and associat- ed nausea. After a drug-free interval of 28 months, he had declined (MMSE 22/30); galantamine was commenced and titrated up to 24 mg/day without headache. In the other patient, simple analgesia controlled headache symptoms but he was unable to increase to donepezil 10 mg/day. Neither patient had a history of prior primary headache disorder or current hypertension. This pragmatic study suggests that the frequency of ChEI-related headache is very low (1.4%, 95% CI=0.5%-3.3%). Hence, although ChEIs may be responsible for "headache induced by acute sub-stance use or exposure" [4] , in clinical practice this is rare, seldom requiring medication withdrawal. Headache mechanism is obscure; it may sometimes be causally related to a cholinomimetic effect [3] . Donepezil has also been reported for migraine prophylaxis [5] .
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